Positive Results For Empagliflozin In Type 1 Diabetes Trials | Latest News RSS feed

Positive Results For Empagliflozin In Type 1 Diabetes Trials - Latest News


Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

INGELHEIM, Germany and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials ... in adults with type 1 diabetes on empagliflo... read more

Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

“These positive Phase 2 data show clinically relevant efficacy, favorable safety profile and dose responsive results in line with our expectations for this proof-of-concept trial in patients with type ... read more

Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch

Healthcare conglomerate Johnson & Johnson's (NYSE: JNJ) long-awaited data from Invokana, its type 2 diabetes blockbuster drug ... Overall, though, these results suggest Invokana is a positive for a va... read more

Looking for another news?


Genetic Risk Score for Type 1 Diabetes Predicts Progression of Disease

Identifying patients at risk for developing type 1 diabetes (T1D) can allow for prevention trials ... results for every progression. This study did have limitations. The first being that the T1D GRS w... read more


Lexicon Likely Looking At Even More Competition In Type 1 Diabetes

Data from Phase III trials ... really use some positive clinical data on new compounds and a better sales trajectory for Xermelo. Although Lilly’s somewhat cryptic release regarding its EASE-2 and EAS... read more

New Lilly, Boehringer Diabetes Drug Performs Well in Trial

“Many patients with type ... 1, or type 2 diabetes, the latter being the most widely spread (about 90% of all reported and documented cases of diabetes). Therefore, the fact that this new drug achieve... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

and INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced that both randomized controlled trials ... in adults with type 1 diabetes on empagl... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials ... empagliflozin 2.5 mg and placebo and higher than placebo in adults with type 1 dia... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us